AIDX
20/20 Biolabs, Inc. Common Stock NASDAQ$1.54
Mkt Cap $7.8M
52w Low $1.45
0.2% of range
52w High $50.00
50d MA $3.22
200d MA $3.22
P/E (TTM)
—
EV/EBITDA
-0.1x
P/B
—
Debt/Equity
-66.8x
ROE
19447.7%
P/FCF
0.0x
RSI (14)
—
ATR (14)
—
Beta
-0.42
50d MA
$3.22
200d MA
$3.22
Avg Volume
288.9K
About
20/20 GeneSystems, Inc. operates as a clinical laboratory testing company focused on cancer screening and viral testing services. The company provides multi-cancer early detection blood testing, including a test called OneTest, and offers viral testing services such as rapid COVID-19 test kits, including the Assure COVID-19 IgG/IgM rapid test. It operates the Clinical Lab Innovation Axcelerator (C…
Recent Filings
8-K · 1.01
! Medium
20/20 Biolabs, Inc. -- 8-K 1.01: Financing / Debt Agreement
20/20 Biolabs (AIDX) secured a debt financing agreement with Streeterville Capital, providing capital access to fund operations and growth initiatives.
Apr 28
8-K
Unknown — 8-K Filing
AIDX's modest 17% revenue growth to only $2.0M signals slow commercialization progress in its AI cancer detection market, raising concerns about path to profitability and cash runway for early-stage biotech investors.
Apr 1
Data updated apr 24, 2026 4:46pm
· Source: massive.com